In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Can we predict adverse events in patients with heart failure with reduced ejection fraction submitted to cardiac resynchronization therapy? The role of MIBG scintigraphy.

Session Poster session 5

Speaker Madalena Coutinho Cruz

Congress : ESC Congress 2017

  • Topic : imaging
  • Sub-topic : Nuclear Imaging
  • Session type : Poster Session
  • FP Number : P4344

Authors : M Coutinho Cruz (Lisbon,PT), A Abreu (Lisbon,PT), M Oliveira (Lisbon,PT), H Santa Clara (Lisbon,PT), V Santos (Lisbon,PT), G Portugal (Lisbon,PT), I Rodrigues (Lisbon,PT), L Almeida Morais (Lisbon,PT), R Ilhao Moreira (Lisbon,PT), P Modas Daniel (Lisbon,PT), S Aguiar Rosa (Lisbon,PT), A Goncalves (Lisbon,PT), M Mota Carmo (Lisbon,PT), R Cruz Ferreira (Lisbon,PT)

M. Coutinho Cruz1 , A. Abreu1 , M. Oliveira1 , H. Santa Clara2 , V. Santos2 , G. Portugal1 , I. Rodrigues1 , L. Almeida Morais1 , R. Ilhao Moreira1 , P. Modas Daniel1 , S. Aguiar Rosa1 , A. Goncalves1 , M. Mota Carmo1 , R. Cruz Ferreira1 , 1Hospital de Santa Marta, Serviço de Cardiologia - Lisbon - Portugal , 2Faculdade de Motricidade Humana - Lisbon - Portugal ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 895

Background: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality, but 1/3 of patients (pts) doesn't respond and the rate of adverse events (AE) is high.

Aim: To determine the predictive value of autonomous nervous system assessment with 123I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy regarding AE and its relationship to CRT response.

Methods: Prospective cohort study of heart failure (HF) pts with reduced ejection fraction submitted to CRT. NYHA class, MIBG scintigraphy, cardiopulmonary exercise testing and echocardiography were performed before (M1) and 3–6 months after CRT (M2). Predictors of AE (all-cause mortality, hospitalization for HF or arrhythmia and cardiac transplantation) 2 years after M2 were determined using multivariate regression analysis. Responders had ≥1 of the following: NYHA decrease ≥1, left ventricle ejection fraction (LVEF) absolute increase >5, LVEF relative increase >15%, peak O2 consumption (VO2) increase >10% and left ventricle end-diastolic or end-systolic volume decrease >15%.

Results: Of the 121 pts analyzed (70±14 years, 69.2% men, 29.1% ischemic, 73.1% baseline NYHA III-IV, baseline LVEF 27±11), 35.5% had ≥1 AE (time to first AE 7.1 months). Overall 70 AE occurred (27 deaths, 15 cardiac deaths, 30 hospitalizations for HF, 12 hospitalizations for arrhythmia and 1 cardiac transplantation) with 18.2% (22) of pts having >1 AE. Pts with AE had lower late heart-to-mediastinum ratio (lHMR) at M1 (1.37±0.25 vs. 1.41 0.24 p 0.043) and M2 (1.28±0.18 vs. 1.46±0.20 p 0.001) and lower early heart-to-mediastinum ratio (eHMR) at M2 (1.39±0.20 vs. 1.51±0.20 p 0.001). These parameters predicted AE in the univariate analysis (OR 0.083 95% CI 0.008–0.870 p 0.038 for lHMR at M1, OR 0.001 95% CI 0.0001–0.109 p 0.004 for lHMR at M2 and OR <0.001 95% CI 0.0001–0.071 p 0.004 for eHMR at M2). In the multivariate model against commonly known predictors of outcome (NYHA class, brain natriuretic peptide (BNP), LVEF and peak VO2), lHMR at M1 (OR 0.036 95% CI 0.002–0.797 p 0.036) and eHMR at M2 (OR <0.001 95% CI 0.0001–0.006 p 0.004) remained independent predictors of AE. Hospitalization for HF was the only component of the composite endpoint independently predicted by MIBG scintigraphy (OR 0.004 95% CI 0.0001–0.790 p 0.041 for lHMR at M2). eHMR at M2 was related to response by LVEF criteria (OR 205.784 95% CI 1.662–25485–822 p 0.030). eHMR at M1 LVEF (OR 15.260 95% CI 1.058–220.164 p 0.045). In responders by LVEF, peak VO2 and LVESV, MIBG scintigraphy parameters remained independent predictors of AE (OR 0.002 92% CI 0.0001–0.301 p 0.015 for lHMR at M1, OR 0.002 95% CI 0.0001–0.301 p 0.015 for lHMR at M2, OR 1.061 95% CI 1.005–1.119 p 0.031 for washout at M1).

Conclusion: MIBG scintigraphy predicted AE with added value to NYHA class, BNP, peak VO2 and LVEF. It was capable of identifying pts at increased risk of AE in spite of response to CRT and could be used to recognize pts in need of new therapies.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are